Continued embrace of precision dosing will reduce costs and optimize clinical outcomes.
Yaning Wang, PhD
Advertisement
CEO, Createrna Science and Technology, former Director of FDA’s Division of Pharmacometrics
Articles by Yaning Wang, PhD
Collecting PK data in late phase trials led to alleviating additional trials, drug approval, and better dosing.
Advertisement
Latest Updated Articles
PK in Late Phase TrialsPublished: February 1st 2012 | Updated:
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
NIH Implements Contingency Plan as Government Shutdown Impacts Research Funding
2
2025 SCRS Global Site Solutions Summit: How Technology Vendors Can Reduce Site Burden and Improve Trial Execution
3
2025 SCRS Global Site Solutions Summit: How to Streamline Site Qualification and Initiation Training
4
AI Everywhere: Architecting the Future of Clinical Trials
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
